Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere


A Phase 2/3 Multicenter, Randomized, Double Blind Study of Docetaxel (Taxotere) Plus DN-101 or Placebo in Androgen Independent Prostate Cancer (AIPC)




The purposes of this study are to determine if DN-101 plus Taxotere lowers PSA levels, delays or limits disease progression and is safe with minimal side effects.

Study Status: Active, not recruiting


Condition Intervention Phase
Prostate Cancer Drug: calcitriol
Drug: docetaxel
Phase 2/Phase 3

Verified by Novacea February, 2005

Sponsored by: Novacea
Information provided by: Novacea identifier: NCT00043576

Study Type: Interventional

Study Design: Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

The Cleveland Clinic Foundation, Taussig Cancer Center
Cleveland, Ohio 44195
United States

Tomasz Beer, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site